TREATMENT OF PEOPLE WITH COVID-19 WITHIN THE USAGE OF GENETICALLY ENGINEERED MEANS
DOI:
https://doi.org/10.11603/1681-2727.2022.2.13193Keywords:
COVID-19, monoclonal antibodies, mesenchymal stem cellsAbstract
SUMMARY. One of the most relevant topics today is a viral infection caused by the coronavirus SARS-CoV-2, which has acquired not only medical but also social significance. The World Health Organization declared COVID-19 pandemic on March 11, 2020. Modern therapeutic options for the treatment of COVID-19 combine using drugs that affect both the virus and the components of the body's immune response. Despite the fact that pathogenetic mechanisms of infectious diseases have been partially studied, the treatment still does not live up to expectations, mainly due to the development of adverse drug reactions and conflicting treatment outcomes. Currently, the number of experimental genetically engineered molecules, proposed for the treatment of SARS-CoV-2, are growing steadily, which necessitates the analysis of modern scientific sources on the prospects, advantages and disadvantages of virus-neutralizing monoclonal antibodies, natural killers, mesenchymal stem cells and monoclonal antibodies to interleukin-6.
References
Kokudo, N., & Sugiyama, H. (2020). Call for international cooperation and collaboration to effectively tackle the COVID-19 pandemic. Global Health & Medicine, 2(2), 60-62..
Saba, S., Maryam, K., Zelal, J. K. (2020). Potential strategies for combating COVID-19. Arch Virol., 165(11): 2419–2438. doi: 10.1007/s00705-020-04768-3.
Valdez-Cruz, N. A., García-Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., ... & Trujillo-Roldán, M. A. (2021). Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microbial cell factories, 20(1), 1-32. doi: 10.1186/s12934-021-01576-5.
Wang, C., Li, W., Drabek, D., Okba, N., van Haperen, R., Osterhaus, A. D., ... & Bosch, B. J. (2020). A human monoclonal antibody blocking SARS-CoV-2 infection. Nature communications, 11(1), 1-6. doi: 10.1038/s41467-020-16256-y.
Pinto, D., Park, Y. J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., ... & Corti, D. (2020). Structural and functional analysis of a potent sarbecovirus neutralizing antibody. BioRxiv. doi: 10.1101/2020.04.07.023903.
Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., ... & McLellan, J. S. (2020). Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies. Cell, 181(5), 1004-1015.
Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., ... & Walker, L. M. (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science, 369(6504), 731-736.
Du, S., Cao, Y., Zhu, Q., Yu, P., Qi, F., Wang, G., ... & Qin, C. (2020). Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell, 183(4), 1013-1023. doi: 10.1016/j.cell.2020.09.035
Baum, A., Ajithdoss, D., Copin, R., Zhou, A., Lanza, K., Negron, N., ... & Kyratsous, C. A. (2020). REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science, 370(6520), 1110-1115.
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., & Bhore, R. (2021). REGN-COV2, un cóctel de anticuerpos neutralizantes, en pacientes ambulatorios con Covid-19. N Engl J Med, 384(3), 238-251.
Baum, A., Ajithdoss, D., Copin, R., Zhou, A., Lanza, K., Negron, N., ... & Kyratsous, C. A. (2020). REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science, 370(6520), 1110-1115.
Du, S., Cao, Y., Zhu, Q., Yu, P., Qi, F., Wang, G., ... & Qin, C. (2020). Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell, 183(4), 1013-1023. doi: 10.1016/j.cell.2020.09.035
Coomes, E. A., & Haghbayan, H. (2020). Interleukin-6 in COVID-19: a systematic review and meta-analysis. Reviews in medical virology, 30(6), 1-9. doi: 10.1002/rmv.2141.
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., ... & Yancopoulos, G. D. (2021). REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. New England Journal of Medicine, 384(3), 238-251. doi: 10.1056/NEJMoa2035002.
Flude, B. M., Nannetti, G., Mitchell, P., Compton, N., Richards, C., Heurich, M., ... & Bassetto, M. (2021). Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses, 13(2), 312.
Zhu, J., Pang, J., Ji, P., Zhong, Z., Li, H., Li, B., & Zhang, J. (2020). Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. Journal of medical virology. doi: 10.1002/jmv.26085
Lescure, F. X., Honda, H., Fowler, R. A., Lazar, J. S., Shi, G., Wung, P., ... & Boell, B. (2021). Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine, 9(5), 522-532.
Li, H., Liu, S. M., Yu, X. H., Tang, S. L., & Tang, C. K. (2020). Coronavirus disease 2019 (COVID-19): current status and future perspectives. International journal of antimicrobial agents, 55(5), 105951. doi: 10.1016/j.ijantimicag.
Golchin, A., Seyedjafari, E., & Ardeshirylajimi, A. (2020). Mesenchymal stem cell therapy for COVID-19: present or future. Stem cell reviews and reports, 16(3), 427-433.
Bari, E., Ferrarotti, I., Saracino, L., Perteghella, S., Torre, M. L., & Corsico, A. G. (2020). Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use. Cells, 9(4), 924.
Zhao, R. C. (2020). Stem cell–based therapy for coronavirus disease 2019. Stem Cells and Development, 29(11), 679-681. doi: 10.1089/scd.2020.0071.
Gediz Erturk, A., Sahin, A., Bati Ay, E., Pelit, E., Bagdatli, E., Kulu, I., ... & Yildirim, T. (2021). A multidisciplinary approach to Coronavirus disease (COVID-19). Molecules, 26(12), 3526. doi:10.3390/molecules26123526
Gralinski, L. E., & Menachery, V. D. (2020). Return of the Coronavirus: 2019-nCoV. Viruses, 12(2), 135. doi: 10.3390/v12020135.
Peng, X. L., Cheng, J. S. Y., Gong, H. L., Yuan, M. D., Zhao, X. H., Li, Z., & Wei, D. X. (2021). Advances in the design and development of SARS-CoV-2 vaccines. Military Medical Research, 8(1), 1-31. doi:10.1186/s40779-021-00360-1
Owji, H., Negahdaripour, M., & Hajighahramani, N. (2020). Immunotherapeutic approaches to curtail COVID-19. International immunopharmacology, 88, 106924. doi: 10.1016/j.intimp.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Infectious diseases
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
